A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

15868KRT-232-115OpenA Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to RuxolitinibNCT06479135IndustrialAdultTreatmentIII (Cancer Control)YGlobalOtherCunningham, JuliaGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterCell Therapy; LeukemiaOncology GroupLombardi Comprehensive Cancer Center (LCCC)2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>